Costo efficacia di peginterferone α-2a + ribavirina verso peginterferone α-2b + ribavirina nel trattamento dell’epatite cronica di tipo C in pazienti non pretrattati
- 8 Downloads
- 1 Citations
Cost-effectiveness of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin as initial therapy for patients with Chronic Hepatitis C
Summary
Introduction
The objective of this study was to evaluate the cost-effectiveness of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin as initial therapy for patients with Chronic Hepatitis C (CHC).
Methods
We used a pre-existent Markov model of disease progression in which two cohorts of patients received peginterferon α-2a plus ribavirin or peginterferon α-2b plus ribavirin for 48 weeks and were followed for their expected lifetimes. The reference patient was a 45-year-old male with CHC without cirrhosis. The sustained virological responses (SVR) with peginterferon α-2a plus ribavirin and peginterferon α-2b plus ribavirin, were taken from two different publications. Utilities and costs for each health state were based on literature estimates and on Italian treatment patterns. Costs in 2005 euros and benefits were discounted at 3%. Sensitivity analyses on key clinical and economic parameters were performed. The analysis was conducted from the perspective of the Italian National Health Service.
Results
For the two cohorts expected life-years with peginterferon α-2a plus ribavirin versus peginterferon α-2a plus ribavirin were respectively 30.85 and 30.15 years. Quality-adjusted life years for peginterferon α-2a plus ribavirina were 17.69, and for peginterferon α-2b plus ribavirin were 17.08. The expected cost was €18,272 with peginterferon α-2a plus ribavirin and €18,549 with peginterferon α-2b plus ribavirin.
Conclusion
This economic evaluation suggests that peginterferon α-2a plus ribavirin is a dominant strategy versus peginterferon α-2b plus ribavirin for treatment of adults with CHC, under some assumptions regarding treatment effectiveness and model structure.
Preview
Unable to display preview. Download preview PDF.
Bibliografia
- 1.Craxì A, Licata A. Clinical trial results of peginterferons in combination with ribavirin. Semin Liver Dis 2003; 23 (Suppl. 1): 35–46PubMedGoogle Scholar
- 2.Zeuzem S. Heterogeneous virologic response rates to interferonbased therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004; 140: 370–81PubMedGoogle Scholar
- 3.Sullivan SD, Craxì A, Alberti A, et al. Cost effectiveness of peginterferon α-2a plus ribavirin versus interferon α-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. Pharmacoeconomics 2004; 22: 257–65PubMedCrossRefGoogle Scholar
- 4.Wong JB, Poynard T, Ling MH, et al. Cost-effectiveness of 24 and 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C: International Hepatitis Interventional Therapy Group. Am J Gastroenterol 2000; 95: 1524–30PubMedGoogle Scholar
- 5.Sennfalt K, Reichard O, Hultkrantz R, et al. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden. Scand J Gastroenterol 2001; 36: 870–6PubMedCrossRefGoogle Scholar
- 6.Stein K, Rosenberg W, Wong J. Cost effectiveness of combination therapy for hepatitis C: a decision analytic model. Gut 2002; 50: 253–8PubMedCrossRefGoogle Scholar
- 7.Siebert U, Sroczynski G, Rossol S, et al. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 53: 425–32CrossRefGoogle Scholar
- 8.Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C: the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825–32PubMedCrossRefGoogle Scholar
- 9.Younossi ZM, Singer ME, McHutchison JG, et al. Cost effectiveness of interferon alpha-2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999; 30: 1318–24PubMedCrossRefGoogle Scholar
- 10.Hadziyannis SJ, Sette H jr, Morgan TR, et al. Peginterferon α-2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 1–12Google Scholar
- 11.Manns MP, McHutchinson JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–65PubMedCrossRefGoogle Scholar
- 12.Munari LM, Picciotto A. Recombinant interferon α-2b therapy of chronic hepatitis C in Italy: an economic analysis. Trends Exp Clin Med 1996; 6: 347–53Google Scholar
- 13.Torrance GW, Feeny DH, Furlong WJ, et al. Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Med Care 1996; 34: 702–22PubMedCrossRefGoogle Scholar
- 14.Drummond MF, O’Brien BJ, Stoddart GL, Torrance GW. (Edizione italiana a cura di Fattore G, Garattini L, Lucioni C). Metodi per la valutazione economica dei programmi sanitari. Roma: Il Pensiero Scientifico Editore, 2000Google Scholar
- 15.Weinstein MC, Fineberg HV. L’analisi della decisione in medicina clinica. Milano: Fondazione Smith Kline-FrancoAngeli, 1984Google Scholar
- 16.Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127: 875–81PubMedGoogle Scholar
- 17.Lau DT-Y, Kleiner DE, Ghany MG, et al. 10-year follow-up after interferon-α therapy for chronic hepatitis C. Hepatology 1998; 28: 1121–7PubMedCrossRefGoogle Scholar
- 18.McHutchison JG, Davis GL, Esteben-Mur R, et al. Durability of sustained virologic response in patients with chronic hepatitis C after treatment with interferon a-2b alone or in combination with ribavirin. Hepatology 2001; 34: 244A [abstract]Google Scholar
- 19.Flamm SL, Goldman J, Cahan J, et al. Peg IFN alfa 2b 1.0 mcg/kg/wk is equally effective as Peg-IFN alfa 2b 1.5 mcg/kg/wk plus ribavirin: preliminary SVR results of a prospective, randomized controlled multicenter trial. Hepatology 2004; supplement; Abstract presented at AASLD, 55th — 2004.Google Scholar
- 20.Krawitt CEL, Grace ND, Gordon SR, et al. Comparison of low dose with standard dose peginterferon alfa-2b plus ribavirin for initial treatment for chronic hepatis C. Hepatology 2003; supplement; Abstract presented at AASLD, 54th — 2003Google Scholar
- 21.Meyer-Wiss B, Rich P, Hebling B, et al. Comparison of two peginterferon alfa-2b doses (1.0 versus 1.5 mcg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up moderate fibrosis. Hepatology 2004; supplement; Abstract presented at AASLD, 55th — 2004.Google Scholar